These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26386350)

  • 1. Novel anticoagulants: general overview and practical considerations for dental practitioners.
    Elad S; Marshall J; Meyerowitz C; Connolly G
    Oral Dis; 2016 Jan; 22(1):23-32. PubMed ID: 26386350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct oral anticoagulants: new drugs and new concepts.
    Levy JH; Spyropoulos AC; Samama CM; Douketis J
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1333-51. PubMed ID: 25523529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of bleeding in patients receiving direct oral anticoagulants.
    Hellenbart EL; Faulkenberg KD; Finks SW
    Vasc Health Risk Manag; 2017; 13():325-342. PubMed ID: 28860793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants (DOACs).
    Vazquez S; Rondina MT
    Vasc Med; 2015 Dec; 20(6):575-7. PubMed ID: 26285587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges.
    Favaloro EJ; Pasalic L; Curnow J; Lippi G
    Curr Drug Metab; 2017; 18(7):598-608. PubMed ID: 28413976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
    Schellings MW; Boonen K; Schmitz EM; Jonkers F; van den Heuvel DJ; Besselaar A; Hendriks JG; van de Kerkhof D
    Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on laboratory assessment for direct oral anticoagulants (DOACs).
    Gosselin RC; Adcock DM; Douxfils J
    Int J Lab Hematol; 2019 May; 41 Suppl 1():33-39. PubMed ID: 31069969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory measurement of the direct oral anticoagulants.
    Dale BJ; Chan NC; Eikelboom JW
    Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants.
    Ten Cate H; Henskens YM; Lancé MD
    Vasc Health Risk Manag; 2017; 13():457-467. PubMed ID: 29263674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation.
    Stacy Z; Richter S
    Clin Appl Thromb Hemost; 2017 Jan; 23(1):5-19. PubMed ID: 26988835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
    van Es N; Büller HR
    Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?
    Lippi G; Favaloro EJ
    Clin Chem Lab Med; 2015 Feb; 53(2):185-97. PubMed ID: 25241734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in the monitoring of direct oral anticoagulant therapy.
    Patel JP; Byrne RA; Patel RK; Arya R
    Br J Haematol; 2019 Mar; 184(6):912-924. PubMed ID: 30697708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dental management of patients on direct oral anticoagulants: Case series and literature review.
    Abayon M; Kolokythas A; Harrison S; Elad S
    Quintessence Int; 2016; 47(8):687-96. PubMed ID: 27574712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation.
    Sarma A; Giugliano RP
    Hosp Pract (1995); 2015; 43(5):258-67. PubMed ID: 26559852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
    Darius H
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality and safety issues of direct oral anticoagulants in the emergency department.
    Cervellin G; Benatti M; Bonfanti L; Lippi G
    Semin Thromb Hemost; 2015 Apr; 41(3):348-54. PubMed ID: 25839867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring and reversal strategies for new oral anticoagulants.
    Vanden Daelen S; Peetermans M; Vanassche T; Verhamme P; Vandermeulen E
    Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):95-103. PubMed ID: 25431993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.